Ideal anticoagulation for use with a left ventricular assist device

Area of Science:

• Cardiovascular Science
• Hematology
• Biomedical Engineering

Background:

• Left ventricular assist devices (LVADs) are crucial for heart failure management.
• Effective anticoagulation is essential to prevent device thrombosis and bleeding complications.
• Current anticoagulation strategies require optimization for LVAD therapy.

Purpose of the Study:

• To evaluate the efficacy of various anticoagulants for LVAD support.
• To determine the optimal anticoagulant regimen for balancing coagulation and fibrinolysis.
• To identify strategies that minimize bleeding risks associated with LVADs.

Main Methods:

• Comparative study administering different anticoagulants: heparin, argatroban, protease inhibitor (nafamostat mesilate/FUT-175) alone, and a prostacyclin analogue (PG) with FUT-175.
• Assessment of blood coagulation and fibrinolysis activation markers.
• Evaluation of bleeding tendencies in relation to anticoagulant administration.

Main Results:

• LVAD support without anticoagulation markedly activates coagulation and fibrinolysis.
• Heparin and argatroban administration result in a significant bleeding tendency.
• Nafamostat mesilate (FUT-175) alone causes acceptable levels of coagulation activation.
• Combined administration of a prostacyclin analogue (PG) and FUT-175 effectively balances coagulation and fibrinolysis.

Conclusions:

• The combination of a prostacyclin analogue and nafamostat mesilate (FUT-175) is the most effective anticoagulation strategy for LVADs.
• This combined therapy provides optimal balance between preventing thrombosis and minimizing bleeding.
• Further research into optimized anticoagulation protocols for LVAD patients is warranted.